Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Centre, Randomised, Double-blind, Placebo Controlled Trial to Evaluate the Possible Drug-drug Interaction Between Liraglutide and Paracetamol and the Effects of Liraglutide on Postprandial Glucose and Insulin, Gastric Emptying, Appetite Sensations and Energy Intake in Subjects With Type 2 Diabetes

NCT01517555 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01517555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01517555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Centre, Randomised, Double-blind, Placebo Controlled Trial to Evaluate the Possible Drug-drug Interaction Between Liraglutide and Paracetamol and the Effects of Liraglutide on Postprandial Glucose and Insulin, Gastric Emptying, Appetite Sensations and Energy Intake in Subjects With Type 2 Diabetes
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2006
Completion date
May 31, 2007
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2